- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02868996
An Open Label, Phase 1b, Ascending Dose Study of DM199
December 5, 2017 updated by: DiaMedica Therapeutics Inc
An Open Label, Phase 1b, Single CENTER, Ascending Dose Study TO ASSESS THE SAFETY AND TOLERABILITY of DM199 With a Comparative Pharmacokinetic Study of DM199 Administered Intravenously and a Bioavailability Assessment of Subcutaneous Administration of DM199 in Normal Healthy Subjects
This is a Phase 1B study to assess the safety, tolerability and pharmacokinetics of DM199 in healthy volunteers.
The study will be consist of two parts: Part A will focus on intravenous dosing and Part B will directly compare intravenous dosing with subcutaneous dosing.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Western Australia
-
Perth, Western Australia, Australia
- Linear Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between 18 and 50 years of age (inclusive);
- Healthy with no clinically significant medical problems;
- BMI between 18 to 30 kg/m2 with a weight between 50 to 100 kg (both inclusive);
- No history of alcohol or drug abuse (Paracetamol, Barbiturates, Benzodiazepines, Cocaine, Methadone, Amphetamines, Methamphetamines, Opiates, Phencyclidine, Tetrahydrocannabinol (cannabis), Tricyclic Antidepressants). Subjects should be enrolled only after passing the urine drug screen (positive test for paracetamol will be allowed);
- Non-smokers or light smokers (Less than 5 cigarettes per day) by history and planned during the study;
- No history of significant allergic diathesis such as urticaria, angioedema or anaphylaxis;
- Receiving no chronic medications that affect blood pressure control, the bradykinin or angiotensin system including angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB);
- Willing and able to sign written, informed consent.
Exclusion Criteria:
- Any significant past or current cardiac, pulmonary, hepatic, renal or other medical condition which in the opinion of the investigator would make participation of the subject in this study medically unsafe or compromise the accuracy of assessment of safety, pharmacokinetic and pharmacodynamic data of the study;
- Subjects who have abnormal safety labs outside the local lab ranges will be excluded at PI's discretion based on his/her assessment of clinical significance (can be repeated once at screening at PI's discretion);
- Subjects with past medical history of malignancy except basal cell or squamous cell carcinoma of the skin who have had curative surgical treatment and at least 6 months have elapsed since the procedure;
- A value outside the specified range of 90 mm Hg - 140 mm Hg for systolic blood pressure and 50 mm Hg - 90 mm Hg for diastolic blood pressure (both inclusive) at screening (can be repeated once at screening as per PI's discretion);
- Subjects using angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) to control blood pressure;
- History of clinically significant acute bacterial, viral, or fungal systemic infections in the last 4 weeks prior to screening;
- Clinical or laboratory evidence of an active infection at the time of screening;
- Known alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency);
- Serological evidence of human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (Anti-HCV) at screening;
- Vaccination within 3 months of screening for the study or requiring vaccination during the study or within 3 months after completion of the study;
- Females who are pregnant or nursing;
- Females of childbearing potential (i.e., any woman who is not surgically sterile e.g., hysterectomy, bilateral oophorectomy or >1-year postmenopause status confirmed by follicle-stimulating hormone (FSH) levels as defined by established lab ranges) and all men who, if participating in heterosexual sexual activity that could lead to pregnancy are unable or unwilling to practice medically effective contraception during the study. They should agree to use two reliable methods of contraception (e.g., double-barrier condom plus diaphragm, condom or diaphragm plus a stable dose of hormonal contraception) throughout the study period and until 3 months after receiving study drug. Women of childbearing potential will require compulsory pregnancy testing. A negative pregnancy test (serum and urine) will be documented during screening and at Day -1 respectively;
- Participation in any other drug study within 8 weeks or 5 half-lives of the study drug, whichever is longer;
- Unable or unwilling to comply with the protocol requirements for study visits and procedures;
- Subjects who do not have good venous access for infusion of study drug or for blood sampling;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Low dose (Part A)
Recombinant human tissue kallikrein
|
Intravenous DM199
Other Names:
|
EXPERIMENTAL: Medium low dose (Part A)
Recombinant human tissue kallikrein
|
Intravenous DM199
Other Names:
|
EXPERIMENTAL: Medium high dose (Part A)
Recombinant human tissue kallikrein
|
Intravenous DM199
Other Names:
|
EXPERIMENTAL: High dose (Part A)
Recombinant human tissue kallikrein
|
Intravenous DM199
Other Names:
|
EXPERIMENTAL: Subcutaneous (Part B)
Recombinant human tissue kallikrein
|
Intravenous DM199
Other Names:
|
EXPERIMENTAL: IV (Part B)
Recombinant human tissue kallikrein
|
Intravenous DM199
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 30 days
|
Assessment of safety of intravenous dosing
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of DM199 in plasma
Time Frame: 3 days
|
Assess plasma drug levels
|
3 days
|
Concentration of bradykinin in plasma
Time Frame: 3 days
|
Assess drug associated biomarkers (e.g.
plasma bradykinin levels)
|
3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2016
Primary Completion (ACTUAL)
March 1, 2017
Study Completion (ACTUAL)
March 1, 2017
Study Registration Dates
First Submitted
August 8, 2016
First Submitted That Met QC Criteria
August 11, 2016
First Posted (ESTIMATE)
August 16, 2016
Study Record Updates
Last Update Posted (ACTUAL)
December 7, 2017
Last Update Submitted That Met QC Criteria
December 5, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DM199-2016-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Recombinant human tissue kallikrein
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
DiaMedica Therapeutics IncRecruitingStroke | Ischemic Stroke | Acute StrokeUnited States
-
DiaMedica Therapeutics IncCompletedAcute Ischemic StrokeAustralia
-
Changzhou Qianhong Bio-pharma Co., Ltd.Completed
-
Angde Biotech Pharmaceutical Co., Ltd.Unknown
-
Techpool Bio-Pharma Co., Ltd.UnknownCerebral InfarctionChina
-
Angde Biotech Pharmaceutical Co., Ltd.Beijing Tiantan HospitalUnknown
-
Shandong UniversityShandong Provincial Hospital; The First Affiliated Hospital of Dalian Medical...CompletedImmune ThrombocytopeniaChina
-
Peking Union Medical CollegeShenyang Sunshine Pharmaceutical Co., LTD.UnknownThrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic PurpuraChina
-
Massachusetts General HospitalCompleted